Glenview Trust Co Acquires Shares of 121,885 Edwards Lifesciences Corporation $EW

Glenview Trust Co bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 121,885 shares of the medical research company’s stock, valued at approximately $11,026,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. North Star Asset Management Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $6,475,000. Palo Alto Investors LP purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at $3,043,074,000. Empowered Funds LLC purchased a new stake in Edwards Lifesciences during the 2nd quarter valued at $3,901,000. United Capital Financial Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $1,807,000. Finally, Old North State Trust LLC bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $278,000. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on EW shares. BTIG Research upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Evercore restated an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Finally, Piper Sandler restated an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $89.97 on Friday. The stock has a market cap of $51.81 billion, a P/E ratio of 51.71, a P/E/G ratio of 2.38 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. The stock’s fifty day moving average is $89.48 and its 200 day moving average is $84.99. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,857 shares of company stock worth $170,305 in the last three months. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.